^
Association details:
Biomarker:ALK V3a
Cancer:Non Small Cell Lung Cancer
Drug Class:ALK inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Published date:
12/03/2020
Excerpt:
A total of 84 patients received ALK inhibitor(s) treatment while they were in advanced stage….Of note, patients with ALK V3a/b exhibited a worse OS (HR 4.24 [95% CI 1.01–17.79], P = 0.049)…
DOI:
10.1038/s41598-020-78152-1